RECRUITING

Cefixime Clinical Trial

Talk to us

Conditions

SyphilisHuman Immunodeficiency VirusCefiximeTreponema pallidumPenicillinEarly Syphilis

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to evaluate the efficacy of cefixime compared to benzathine penicillin G in the treatment of syphilis.

Official Title

Clinical Trial Comparing the Effectiveness of Cefixime Versus Penicillin G for Treatment of Early Syphilis

Quick Facts

Study Start:2021-06-20
Study Completion:2025-06-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT04958122

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosed cases of primary, secondary, or early latent syphilis with RPR titer ≥1:8 within 3 weeks prior to enrollment
  2. * 18 years of age or older
  3. * Able to provide informed consent
  4. * Individuals with HIV infection must be on treatment for HIV infection and virologically suppressed (viral load \<200 copies/mL) or have a CD4 count ≥ 350 cells/mm3 according to most recent labs before study enrollment
  1. * Pregnancy or a positive pregnancy test on the day of enrollment
  2. * Patients showing signs and symptoms of neurosyphilis
  3. * Serofast RPR titer, defined as persistently positive RPR titer without more than 4-fold (2-titer level) change for 12 months or greater
  4. * Recent (within the past 7 days) or concomitant antimicrobial therapy with activity against syphilis, namely azithromycin, doxycycline, ceftriaxone, or other beta-lactam antibiotics (e.g. amoxicillin)
  5. * Individuals with HIV infection who report HIV treatment interruption for more than 4 weeks since their most recent viral load or CD4 test
  6. * Self-reported allergy to cephalosporins or penicillin
  7. * Unwilling or unable to attend follow-up visits

Contacts and Locations

Study Contact

Jeffrey D Klausner
CONTACT
(415) 876-8901
jdklausner@med.usc.edu

Principal Investigator

Jeffrey D Klausner, MD MPH
PRINCIPAL_INVESTIGATOR
University of Southern California

Study Locations (Sites)

University of Southern California
Los Angeles, California, 90032
United States

Collaborators and Investigators

Sponsor: University of Southern California

  • Jeffrey D Klausner, MD MPH, PRINCIPAL_INVESTIGATOR, University of Southern California

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-20
Study Completion Date2025-06-30

Study Record Updates

Study Start Date2021-06-20
Study Completion Date2025-06-30

Terms related to this study

Keywords Provided by Researchers

  • Cefixime
  • Treponema pallidum
  • Penicillin
  • Early Syphilis

Additional Relevant MeSH Terms

  • Syphilis
  • Human Immunodeficiency Virus